Twelve hospitals, including NYC’s Memorial Sloan Kettering, have been chosen to participate in the new pancreatic cancer treatment model known as Precision Promise. This clinical trial, due to start in spring of 2017, will find the right treatment for each patient. Participants will be able to participate in many different substudies of various experimental treatments, as their tumors’ shift, reports Susan Keown of Fred Hutch News Service.
The launch of Precision Promise “is a huge moment,” said Dr. Vincent Picozzi, pancreatic cancer specialist at Virginia Mason Medical Center. “If it works out the way we hope, it will completely change how pancreatic cancer research as a whole is pursued nationwide.”
